PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Like Pear Therapeutics, Omada Health also competes in the Application Software industry. B y Sam Nussey. The top 10 competitors average 378. BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that it has successfully closed a $64 million Series C … Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. December 08, 2020. By Dave Muoio. Pear Therapeutics Inc. is a software-based biotechnology company based in Massachusetts, USA. List of Pear Therapeutics 's 4 Funding Rounds from 9 Investors Save Search Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. In January of this year, my company, Pear Therapeutics, commercially launched the first FDA-authorized PDTs, reSET for substance use disorder and reSET-O for opioid use disorder. Get the full list », You’re viewing 5 of 19 investors. Pear Therapeutics is the leader in prescription digital therapeutics. Curalie. Developer of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy via Prescription Digital Therapeutics (PDT). At Pear, our mission is clear: we are pioneers in PDTs. EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). We aim to redefine medicine by discovering, developing, and delivering … We are leading the development of a new segment in the healthcare industry, prescription digital therapeutics, or PDTs. FOUNDED. EquityZen does not have an affiliation with, formal relationship with, or endorsement from Pear Therapeutics or any companies feature above. Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. Mindstrong Health is transforming the diagnosis and treatment of behavioral health disorders through the ubiquity of mobile technology. By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.© 2020 EquityZen Inc. All rights reserved. WuXi NextCODE, Sprinklr, Druva, Pear Therapeutics, Paxata, Pear Therapeutics, Akili Interactive Labs, Pymetrics, Halo Neuroscience, Tokopedia, DoorDash, Impossible Foods, Wish, AvidXchange, Carbon, Improbable, Farmer's Business Network, Guardant Health, Rent the Runway. Pear Therapeutics has enrolled the first participant in the DREAM study, an open-label trial of its Somryst prescription digital therapeutic for chronic insomnia. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to Curalie is a company that builds digital healthcare products. Pear Therapeutics highlighted data today from two studies of a digital cognitive behavioral therapy that acted as the precursor for Somryst, the prescription digital therapeutic for adults with chronic insomnia that was the first to pass through the FDA's Pre-Cert pilot pathway. Pear Therapeutics director outlines challenges of regulated software design MobiHealthNews 4/04/19 Pharma Giants Like Novartis and Sanofi Are Betting That The Futre of Healthcare Looks More Like an App or Sensor Than a Prescription Business Insider 2/20/19 Pear Therapeutics rakes in $64M for reSET commercialization, product development. Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Hygieia. Pear is a small, mission-driven company that is truly innovating by developing some of the first prescription digital therapies for mental health. Get the full list », You’re viewing 5 of 15 board members. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform. Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. Several companies, including Pear Therapeutics and Dthera, are taking a wildly different approach: digital therapeutics. Pear Therapeutics has 188 employees and is ranked 4th among it's top 10 competitors. Hygieia is a company that provides insulin therapy for the treatment of … The Company develops digital therapies to address a broad range of severe conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. “Pear Therapeutics has combined biology and software to pioneer the first end-to-end platform for prescription digital products, with an initial focus on serious psychiatric diseases. © 2021 PitchBook Data. Pear Therapeutics has raised $207.77 m in total funding. January 07, 2019. Pear is pioneering the use of software to treat disease with Prescription Digital Therapeutics (PDTs) for a range of unmet medical needs. Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding. Pear Therapeutics, Inc. is the leader in prescription digital therapeutics. Get the full list », You’re viewing 5 of 16 executive team members. The latest funding was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Partners, The Bridge Builders Collaborative and EDBI. Biotech & Pharma. Omada Health was founded in San Francisco, California} in 2011. Get the full list », To view Pear Therapeutics’s complete investments history, request access », Co-Founder, President, Chief Executive Officer & Board Member, Chief Operating Officer & Chief Financial Officer. Funding and IPOs. Company profile page for Pear Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Pear is accessing new technologies to expand its PDT platform. The leader in Prescription Digital Therapeutics. Pear Therapeutics is part of a burgeoning category of health start-ups known as digital therapeutics. Kallyope is a healthcare company focusing on biotechnology business. SECTOR. Equity securities are offered through EquityZen Securities. Pear Therapeutics president and CEO Corey McCann (Pear) ... of 2020 and found that the industry rang out the old year with a record $13.5 billion raised from a chart-topping 81 IPOs… A Company of "Firsts" Pear is a place for pioneers: for those with a passion for investigating unchartered territories and boldly advancing medicine and patient treatments. Pear Therapeutics. Pear Therapeutics is a privately held eHealth company with offices in Boston and San Francisco. TOKYO, Dec 8 (Reuters) - SoftBank Group Corp's 9984.T Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics … All rights reserved. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians and cost-effective services for payors. Developer of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy via Presc, t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo cons, ex ea commodo consequat. PitchBook is a financial technology company that provides data on the capital markets. Our cross-functional team operates at the intersection of biology and software technology. … Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. This profile is based on publicly available information and is intended to be informative in nature. SAN FRANCISCO—Pear Therapeutics has posted $64 million in new fundraising on the heels of scoring an FDA clearance last month for its prescription software … Decentralized digital therapeutic trial. INDUSTRY. The Molecular Assemblies story began more than 30 years ago as co- founders, Dr. Bill Efcavitch and Curt Becker, Pear Therapeutics launches digital insomnia app through direct-to-patient telehealth model, Pear Therapeutics Announces Publication of Real-World Healthcare Resource Utilization Data for reSET-O®, Coverage for Pear Therapeutics’ PDTs continues to grow, Pear Therapeutics Announces Collaboration with Apricity Health to Advance Prescription Digital Therapeutics to be Prescribed in Combination with Immuno-oncology Therapy, Pear Therapeutics Expands Pipeline with Machine Learning, Digital Therapeutic and Digital Biomarker Technologies. Health Care. It specializes in using digital therapeutics to treat substance … Corey M. McCann, MD, PhD (Pear Therapeutics) Interview @ 2017 DigitalHealth & Fitness LIVE ... Interview Joel Sangerman/Click Therapeutics - Digital Health Live Studio - … Pear Therapeutics homes in on reimbursement coverage with $80M Series D. The company currently has three prescription digital therapeutics available on the market. Pearl Therapeutics serves customers in the United States. On our trusted digital marketplace for private companies. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor, To view Pear Therapeutics’s complete valuation and funding history, request access », To view Pear Therapeutics’s complete cap table history, request access », You’re viewing 5 of 21 competitors. The company combines pharmaceutical therapy with software technology, such as digital applications and games. Pear Therapeutics is a company developing drug-software combination therapies to help people with mental and behavioral health issues. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear Therapeutics, also referred to as Pear, is a company developing drug-software combination therapies to help people with mental and behavioral health issues. View Pear Therapeutics stock / share price, financials, funding rounds, investors and more at Craft. Investors must be able to afford the loss of their entire investment. EquityZen helps investors to access private companies and their employees to sell shares. Health Care. Description Developer of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy via Prescription Digital Therapeutics (PDT). Check the background of this firm on FINRA’s BrokerCheck. EquityZen is a marketplace for shares of proven pre IPO tech companies. Pear Therapeutics rakes in $64M for reSET commercialization, product development The latest funding was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Partners, The Bridge Builders Collaborative and EDBI. These are pieces of software designed to treat disease that are regulated, prescribed and even paid for as if they were drugs. 12:14 pm. Pear Therapeutics, Inc. is the leader in Prescription Digital Therapeutics. SUB-INDUSTRY. The company's platform discovers, develops, and delivers clinically-validated software to enhance efficacy, enabling physicians to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors. EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Personalize which data points you want to see and create visualizations instantly. PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach. Omada Health is Pear Therapeutics's #1 competitor. The round was led by Singapore-based investment company Temasek, with participation from returning investors 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners, as well as new partners Novartis, EDBI, … By Laura Lovett.